Skip to main content
. 2017 Aug 16;14(4):3874–3879. doi: 10.3892/etm.2017.4941

Figure 3.

Figure 3.

Kaplan-Meier estimate of cumulative incidence of relapse (CIR) of Philadelphia-positive acute lymphoblastic leukemia (Ph+-ALL) patients. The CIR time of patients with dominant-negative Ikaros 6 (DN-IK6) isoform (n=17) was significantly higher than those without IK6 isoform (n=11) in the patients with Ph+- ALL. (log-rank χ2=5.50, P<0.05). The status means the censored data of two groups, which were DN-IK6 group and the non-DN-IK6 group in the patients with Ph+-ALL.